BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 20686456)

  • 1. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
    Gaebel W; Schreiner A; Bergmans P; de Arce R; Rouillon F; Cordes J; Eriksson L; Smeraldi E
    Neuropsychopharmacology; 2010 Nov; 35(12):2367-77. PubMed ID: 20686456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
    de Arce Cordón R; Eding E; Marques-Teixeira J; Milanova V; Rancans E; Schreiner A
    Eur Arch Psychiatry Clin Neurosci; 2012 Mar; 262(2):139-49. PubMed ID: 21809168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
    Llorca PM; Sacchetti E; Lloyd K; Kissling W; Medori R
    Int J Clin Pharmacol Ther; 2008 Jan; 46(1):14-22. PubMed ID: 18218293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
    Mullen J; Jibson MD; Sweitzer D
    Clin Ther; 2001 Nov; 23(11):1839-54. PubMed ID: 11768836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
    Meltzer HY; Lindenmayer JP; Kwentus J; Share DB; Johnson R; Jayathilake K
    Schizophr Res; 2014 Apr; 154(1-3):14-22. PubMed ID: 24630262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
    Glick ID; Marder SR
    J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
    Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
    Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
    Rouillon F; Eriksson L; Burba B; Raboch J; Kaprinis G; Schreiner A
    Acta Neuropsychiatr; 2013 Oct; 25(5):297-306. PubMed ID: 25287730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis.
    Malla A; Chue P; Jordan G; Stip E; Koczerginski D; Milliken H; Joseph A; Williams R; Adams B; Manchanda R; Oyewumi K; Roy MA
    Clin Schizophr Relat Psychoses; 2016; 9(4):198-208. PubMed ID: 23773886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
    Potkin SG; Thyrum PT; Alva G; Bera R; Yeh C; Arvanitis LA
    J Clin Psychopharmacol; 2002 Apr; 22(2):121-30. PubMed ID: 11910256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.